Psyence Biomedical (PBM) Competitors $0.55 +0.09 (+19.00%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$0.55 +0.00 (+0.58%) As of 04/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBM vs. CTXR, CSCI, GELS, PMCB, APRE, ACXP, TLPH, TSBX, PRTG, and KPRXShould you be buying Psyence Biomedical stock or one of its competitors? The main competitors of Psyence Biomedical include Citius Pharmaceuticals (CTXR), COSCIENS Biopharma (CSCI), Gelteq (GELS), PharmaCyte Biotech (PMCB), Aprea Therapeutics (APRE), Acurx Pharmaceuticals (ACXP), Talphera (TLPH), Turnstone Biologics (TSBX), Portage Biotech (PRTG), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical products" industry. Psyence Biomedical vs. Citius Pharmaceuticals COSCIENS Biopharma Gelteq PharmaCyte Biotech Aprea Therapeutics Acurx Pharmaceuticals Talphera Turnstone Biologics Portage Biotech Kiora Pharmaceuticals Psyence Biomedical (NASDAQ:PBM) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, community ranking, institutional ownership, media sentiment and risk. Does the media refer more to PBM or CTXR? In the previous week, Psyence Biomedical and Psyence Biomedical both had 1 articles in the media. Citius Pharmaceuticals' average media sentiment score of 1.89 beat Psyence Biomedical's score of 1.87 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Psyence Biomedical Very Positive Citius Pharmaceuticals Very Positive Do analysts rate PBM or CTXR? Citius Pharmaceuticals has a consensus target price of $54.50, suggesting a potential upside of 6,319.32%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Psyence Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Citius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is PBM or CTXR more profitable? Psyence Biomedical's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Psyence BiomedicalN/A N/A N/A Citius Pharmaceuticals N/A -51.69%-37.60% Which has more volatility & risk, PBM or CTXR? Psyence Biomedical has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Do insiders and institutionals have more ownership in PBM or CTXR? 77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by company insiders. Comparatively, 12.1% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable valuation and earnings, PBM or CTXR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPsyence BiomedicalN/AN/A-$51.16MN/AN/ACitius PharmaceuticalsN/AN/A-$39.14MN/AN/A Does the MarketBeat Community prefer PBM or CTXR? Citius Pharmaceuticals received 212 more outperform votes than Psyence Biomedical when rated by MarketBeat users. CompanyUnderperformOutperformPsyence BiomedicalN/AN/ACitius PharmaceuticalsOutperform Votes21262.54% Underperform Votes12737.46% SummaryCitius Pharmaceuticals beats Psyence Biomedical on 9 of the 12 factors compared between the two stocks. Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBM vs. The Competition Export to ExcelMetricPsyence BiomedicalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.49M$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.31%P/E RatioN/A7.1422.1418.40Price / SalesN/A238.89389.71101.29Price / CashN/A65.6738.2034.62Price / Book-0.016.266.664.18Net Income-$51.16M$142.48M$3.21B$247.71M7 Day Performance25.50%7.90%6.22%6.61%1 Month Performance-10.89%-4.23%-2.82%-2.21%1 Year Performance-99.15%-2.70%16.44%4.68% Psyence Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBMPsyence BiomedicalN/A$0.55+19.0%N/A-99.1%$2.49MN/A0.00N/APositive NewsGap UpCTXRCitius Pharmaceuticals1.953 of 5 stars$1.00+1.0%$54.50+5,350.0%-95.4%$8.90MN/A0.0020Positive NewsCSCICOSCIENS BiopharmaN/A$2.81-3.5%N/AN/A$8.83M$7.60M-0.2420Gap UpGELSGelteqN/A$0.93+0.0%N/AN/A$8.78MN/A0.00N/ALockup ExpirationPMCBPharmaCyte Biotech1.2071 of 5 stars$1.27+5.8%N/A-42.5%$8.72MN/A2.404Positive NewsGap DownAPREAprea Therapeutics2.5647 of 5 stars$1.58flat$15.50+881.0%-70.6%$8.68M$580,000.00-0.567ACXPAcurx Pharmaceuticals2.0075 of 5 stars$0.38-0.6%$12.00+3,057.9%-80.0%$8.51MN/A-0.353Positive NewsTLPHTalphera2.2823 of 5 stars$0.49-5.2%$4.33+778.1%-56.6%$8.44M$281,000.00-0.7219Positive NewsTSBXTurnstone Biologics2.0488 of 5 stars$0.36-3.7%$0.45+24.0%-87.9%$8.40M$19.31M-0.1182PRTGPortage Biotech0.8453 of 5 stars$7.99-10.0%N/A+78.3%$8.38MN/A-0.196KPRXKiora Pharmaceuticals3.4708 of 5 stars$2.79+1.1%$10.00+258.4%-25.9%$8.37M$16M2.6810Positive News Related Companies and Tools Related Companies Citius Pharmaceuticals Alternatives COSCIENS Biopharma Alternatives Gelteq Alternatives PharmaCyte Biotech Alternatives Aprea Therapeutics Alternatives Acurx Pharmaceuticals Alternatives Talphera Alternatives Turnstone Biologics Alternatives Portage Biotech Alternatives Kiora Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBM) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PBM Stock Free PBM Stock Alerts